 |
|
A Successful System of Scientific Data Audits for Clinical TrialsA Report From the Cancer and Leukemia Group B
Raymond B. Weiss, MD;
Nicholas J. Vogelzang, MD;
Bruce A. Peterson, MD;
Lawrence C. Panasci, MD;
John T. Carpenter, MD;
Molly Gavigan, RN, BSN;
Karen Sartell;
Emil Frei III, MD;
O. Ross McIntyre, MD
JAMA. 1993;270(4):459-464.
Abstract
| |
Objective.
—To report on data collected during on-site audits of source documents in the Cancer and Leukemia Group B (CALGB).
Design.
—A retrospective review of audit reports in four audit cycles.
Setting.
—A cooperative group of institutions conducting clinical trials in cancer treatment.
Participants.
—Patients taking part in clinical trials at collaborating CALGB institutions, members of the CALGB Data Audit Committee, and group chairmen of CALGB.
Main Outcome Measure.
—The results of 691 institutional audits conducted by the CALGB in 1982 through 1992 with comparisons of main CALGB institutions vs affiliates.
Results.
—In four full reviews of all participating institutions in the CALGB, 3787 patients have had their on-site medical records compared with data submitted to the CALGB Data Management Center. Compliance with federal regulations for oversight by an institutional review board improved from a deficiency rate of 28.0% among the main institutions and 49.6% of the affiliate institutions in the first audit cycle to respective figures of 13.3% and 28.2% in the fourth cycle. Consent form deficiencies also dropped overall from 18.5% in the first cycle to 3.9% in the fourth. Patient eligibility was verified by auditors in 94.5%, and assessment of tumor changes in response to treatment was verified in 96.4% in the fourth cycle; both figures were only slightly lower in the first cycle. Two instances of scientific impropriety were discovered for a rate of only 0.28% of all audits. Both occurred prior to 1984, and none have occurred since. Major protocol deviations in drug dosing have held steady at about 11% over four audit cycles. Over the 11-year period of audits, three main institutions and 96 affiliate institutions have discontinued CALGB membership due solely, or at least partly, to unfavorable audit results.
Conclusion.
—Scientific improprieties have occurred very rarely in clinical trials conducted by the CALGB. Protocol compliance in assessing patient eligibility and tumor responses has been high. Attention to administrative matters of consent forms, institutional review board approval, and ancillary data submission has measurably improved in the CALGB, which is at least partly due to the pressure from this on-site peer review of investigator performance.
(JAMA. 1993;270:459-464)
Author Affiliations
From the Department of Medicine, Walter Reed Army Medical Center, Washington, DC (Dr Weiss); Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Md (Dr Weiss); Department of Medicine, University of Chicago (Ill) (Dr Vogelzang); Department of Medicine, University of Minnesota, Minneapolis (Dr Peterson); Department of Medicine, McGill Cancer Center, Montreal, Quebec (Dr Panasci); Department of Medicine, University of Alabama, Birmingham (Dr Carpenter); Department of Medicine, University of North Carolina, Chapel Hill (Ms Gavigan); the Central Office of the Cancer and Leukemia Group B, Lebanon, NH (Ms Sartell and Dr McIntyre); Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, Mass (Dr Frei); and Department of Medicine, Dartmouth Medical School, Hanover, NH (Dr McIntyre).
Footnotes
The opinions expressed in this article are solely those of the authors and are not necessarily those of any government agency.
Reprint requests to Section of Medical Oncology, Walter Reed Army Medical Center, Washington, DC 20307 (Dr Weiss).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Scientific misconduct from the perspective of research coordinators: a national survey
Pryor et al.
J. Med. Ethics 2007;33:365-369.
ABSTRACT
| FULL TEXT
Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222
Moore et al.
Blood 2005;105:3420-3427.
ABSTRACT
| FULL TEXT
Dose Escalation Studies of Cytarabine, Daunorubicin, and Etoposide With and Without Multidrug Resistance Modulation With PSC-833 in Untreated Adults With Acute Myeloid Leukemia Younger Than 60 Years: Final Induction Results of Cancer and Leukemia Group B Study 9621
Kolitz et al.
JCO 2004;22:4290-4301.
ABSTRACT
| FULL TEXT
A reporting tool for real-time assessment of study data availability
Bosch et al.
Clin Trials 2004;1:339-340.
ABSTRACT
Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720
Baer et al.
Blood 2002;100:1224-1232.
ABSTRACT
| FULL TEXT
An On-Site Audit of the South African Trial of High-Dose Chemotherapy for Metastatic Breast Cancer and Associated Publications
Weiss et al.
JCO 2001;999:1-8.
ABSTRACT
| FULL TEXT
An On-Site Audit of the South African Trial of High-Dose Chemotherapy for Metastatic Breast Cancer and Associated Publications
Weiss et al.
JCO 2001;19:2771-2777.
ABSTRACT
| FULL TEXT
Parallel Phase I Studies of Daunorubicin Given With Cytarabine and Etoposide With or Without the Multidrug Resistance Modulator PSC-833 in Previously Untreated Patients 60 Years of Age or Older With Acute Myeloid Leukemia: Results of Cancer and Leukemia Group B Study 9420
Lee et al.
JCO 1999;17:2831-2831.
ABSTRACT
| FULL TEXT
A Randomized Controlled Trial of Filgrastim During Remission Induction and Consolidation Chemotherapy for Adults With Acute Lymphoblastic Leukemia: CALGB Study 9111
Larson et al.
Blood 1998;92:1556-1564.
ABSTRACT
| FULL TEXT
Granulocyte Colony-Stimulating Factor (Filgrastim) Accelerates Granulocyte Recovery After Intensive Postremission Chemotherapy for Acute Myeloid Leukemia With Aziridinyl Benzoquinone and Mitoxantrone: Cancer and Leukemia Group B Study 9022
Moore et al.
Blood 1997;89:780-788.
ABSTRACT
| FULL TEXT
The National Cancer Institute Audit of the National Surgical Adjuvant Breast and Bowel Project Protocol B-06
Christian et al.
NEJM 1995;333:1469-1475.
ABSTRACT
| FULL TEXT
Definitive vs. Exploratory Periodontal Trials: A Survey of Published Studies
Hujoel
JDR 1995;74:1453-1458.
ABSTRACT
Granulocyte-Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia
Stone et al.
NEJM 1995;332:1671-1677.
ABSTRACT
| FULL TEXT
Lessons from the Pearce affair: handling scientific fraud
Lock
BMJ 1995;310:1547-1547.
FULL TEXT
Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia
Mayer et al.
NEJM 1994;331:896-903.
ABSTRACT
| FULL TEXT
Data Audit for Clinical Trials
Wilson
JAMA 1993;270:2685-2685.
ABSTRACT
Accountability, Audit, and Reverence for the Publication Process
Rennie
JAMA 1993;270:495-496.
ABSTRACT
|
